Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update

What happened

Precision BioSciences reported results for the third quarter ended September 30, 2026, and provided a business update. It said it continued advancing its PBGENE-HBV therapy in a chronic hepatitis B trial and began dosing the first patient in its FUNCTION-DMD trial for Duchenne muscular dystrophy.

Confirmed

Global impact / market context

Starting dosing means the Duchenne program has moved into testing in people, while progress in the hepatitis B trial could produce clinical data for investors to assess. Those milestones may influence expectations for development costs, future trial decisions, and the company’s ability to advance its therapies.

Analyst inference

The supplied update describes two clinical programs but gives no financial figures, trial results, or regulatory decisions. For investors, progress in early human testing is not proof of safety or benefit; upcoming data and later study decisions will determine whether either program advances.

Analyst inference

What to watch

1. Precision said it expects to present PBGENE-HBV clinical data at the AASLD Liver Meeting on November 8 at 2 p.m. MST; the findings may clarify trial progress. Confirmed
2. Watch for details on the FUNCTION-DMD trial after its first patient was dosed, including whether additional participants begin treatment and what evidence emerges about safety. Analyst inference
3. The article provides no financial results or trial outcomes, so future disclosures on cash available, development spending, and clinical findings would help gauge funding needs and progress. Analyst inference

Evidence

• Original source link unavailable